BlackRock Fund Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

BlackRock Fund Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$28.9M	Buy	1,398,009 +80,278	+6%	+$1.34M	0.01%	1980
2016 Q3	$21.4M	Buy	1,317,731 +123,376	+10%	+$1.79M	﹤0.01%	2034
2016 Q2	$16.2M	Buy	1,194,355 +43,856	+4%	+$775K	﹤0.01%	2144
2016 Q1	$20.1M	Buy	1,150,499 +100,774	+10%	+$2.05M	﹤0.01%	1990
2015 Q4	$35.9M	Buy	1,049,725 +296,761	+39%	+$10.3M	0.01%	1705
2015 Q3	$22.4M	Buy	752,964 +31,965	+4%	+$971K	0.01%	1923
2015 Q2	$23.1M	Buy	720,999 +179,272	+33%	+$4.61M	0.01%	2025
2015 Q1	$11.2M	Buy	541,727 +26,135	+5%	+$452K	﹤0.01%	2379
2014 Q4	$8.73M	Buy	515,592 +313,956	+156%	+$5.48M	﹤0.01%	2540
2014 Q3	$3.9M	Buy	201,636 +25,322	+14%	+$660K	﹤0.01%	2883
2014 Q2	$6M	Sell	176,314 -13,433	-7%	-$421K	﹤0.01%	2735
2014 Q1	$5.98M	Buy	+189,747	New	+$5.93M	﹤0.01%	2712

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors's RVNC Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Revance Therapeutics, Inc. (RVNC) stake by 6.1% in Q4 2016, buying an estimated $1.34M and bringing the position to 1,398,009 shares worth $28.9M. The position accounts for 0.01% of the portfolio, ranked #1980.

BlackRock Fund Advisors first reported a position in RVNC in Q1 2014 and has held it in 12 quarters since. The position peaked at $35.9M in Q4 2015. 81 funds tracked by Wall St. Rank hold RVNC as of Q4 2016.

BlackRock Fund Advisors held 1,398,009 shares of Revance Therapeutics, Inc. worth $28.9M as of Q4 2016.
BlackRock Fund Advisors bought 80,278 Revance Therapeutics, Inc. shares in Q4 2016, an estimated $1.34M.
Revance Therapeutics, Inc. made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1980 holding.
BlackRock Fund Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Revance Therapeutics, Inc. position peaked at $35.9M in Q4 2015.
81 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.